Page 25 - Syndipharma

Avicenna Laboratories Inc.

IRANIAN PHARMACEUTICAL COMPANIES DIRECTORY

Founded: 2003

HQ Office: No. 8 ,23 St, Yousefabad Jahanara Ave, Tehran, Iran
rd
Plant Location: Factory address:Kaveh Industrial City ,Saveh,Iran

Major Shareholder: Dr. khashayar karimian

Employees: Total number of personnel working in the Pharmaceutical is comprised of 150

Company Profile:
Avicenna Laboratories Inc. is a subsidiary of Ajand Pharmaceutical Holding Inc
Avicenna Laboratories Inc. is a manufacturer of solid dosage form of drug products. Founded in 2003, the company
supplies various drug products to domestic and international clients. Regulatory Affairs, Sales, Marketing and oth-
er administrative functions as well as Formulation R&D are conducted through our head office and laboratories in
Tehran. Material Management, Quality Control, and Manufacturing are located in two separate factories in Kaveh
Industrial Park 90 km south of Tehran.
Avicenna was granted a Science-Based Company status by the Office of the Vice President for Research and Develop-
ment in 2016. This was based on Avicenna’s record of excellence in Research and Development as demonstrated in
scientific publications and international patents.
Avicenna was the recipient of the Technology-Quality Award in Pharmaceutical Industry by European Union (ICS
Group)

Production Lines:
FACILITIES
20,000 sq. meter complex includes process and formulation development and QC laboratories, Material Manage-
ment, Production, Packaging, Utilities, water purification (RO), Water Treatment and raw material and finished
product Warehouses.
State-of-the-art equipment and all other requirements for the production of solid dosage forms of drugs(tablets
and capsules).
Extensive water treatment facility.
Consistently lower levels of BOD and COD of effluent water than those required by the Environmental Protection
Organization.

QUALITY CONTROL AND QUALITY ASSURANCE
State-of-the-art laboratories and equipment such as HPLCs, GCs, UV, IR Atomic Absorption, polarimeter, etc.
Extensive records of CAPA based on statistical analysis of data.
Full implementation of Quality System (QS) as described in ICH Q10.
Continuing in-house and off-site training of personnel on quality-related issues.

REGULATORY AFFAIRS
Strict adherence to over 1000 comprehensive Standard Operating Procedures (SOPs).
Strict adherence to cGMP guidelines as set by the FDA and the ICH and regulation of 21 CFR Part 211.
Continuing in-house and off-site training of personnel on cGMP –related matters.

24